Vesigen to Present New Preclinical Data on Engineered ARMMs Technology at 2024 ASGCT Annual Meeting

CAMBRIDGE, Mass., April 22, 2024 /Business Wire/ — Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform for gene editors, RNA, and protein-based therapeutics, today announced that the Company will be presenting 10 posters sharing new preclinical data from its engineered ARMMs platform at the upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting. The conference will be held from May 7-11 in Baltimore, Maryland.

Vesigen’s delivery technology has been shown to be non-immunogenic and is re-dosable. ARMMs can be targeted to cell types of interest. Vesigen will be presenting new preclinical data demonstrating successful biodistribution of its ARMMs in non-human primates (NHPs). The team will also be sharing data on its new targeted ARMMs technology, demonstrating the ability to deliver to otherwise hard-to-reach cell types.

Details of the poster presentations are listed below. All posters will be presented in the poster hall of the Baltimore Convention Center at 12 PM EST.

May 8 Poster Presentations

Engineering ARMMs with Engagers to Direct Biodistribution to Specific Neurons as a Therapeutic Strategy for Friedreich Ataxia

  • Presenting Author: Wendy Zhao, Ph.D.
  • Abstract Number: 635

ARMMs as Non-Viral Vehicles for the Delivery of Genome Editors to Treat Inherited Retinal Diseases

  • Presenting Author: Qin Yu, Ph.D.
  • Abstract Number: 660

Biodistribution of ARMMs as Non-Viral Vehicles for Therapeutic Payloads by Subretinal Administration in Minipigs and Non-Human Primates

  • Presenting Author: Joseph Nabhan, Ph.D.
  • Abstract Number: 663

 May 9 Poster Presentations

ARMMs as Non-Viral Vehicles for the Delivery of Therapeutic Payloads to Liver Sinusoidal Endothelial Cells

  • Presenting Author: Ryan von Kleeck, Ph.D.
  • Abstract Number: 1238

Fractionation of distinct extracellular vesicle populations by charge and density to evaluate the heterogeneity and purity of ARMMs

  • Presenting Author: Kristin Luther, Ph.D.
  • Abstract Number: 1246

ARMMs as a Versatile and Modular Non-Viral Platform for the Functional Delivery of Genome Editors

  • Presenting Author: Qiyu Wang, Ph.D.
  • Abstract Number: 1247

Engineering ARMMs with Modular T Cell-Specific Engagers for Non-Viral Delivery of Therapeutic Payloads

  • Presenting Author: Wendy Zhao, Ph.D.
  • Abstract Number: 1248

Engineering Directed Tropism in the Non-Viral ARMMs Delivery Platform

  • Presenting Author: Silvia Piccinotti, Ph.D.
  • Abstract Number: 1249

 May 10 Poster Presentations

ARMMs as Non-Viral Vehicles that Enable in vivo Functional Delivery of Cas9 to Disrupt NLRP3 in Kupffer Cells and Ameliorate Acute Liver Injury

  • Presenting Author: Mike Thomas, Ph.D.
  • Abstract Number: 1736

Suspension Cell-Based Production and Scalable Purification of Engineered ARMMs as a Platform for Non-Viral Therapeutics

  • Presenting Author: Steven Greenway
  • Abstract Number: 1746

For more information about the ASGCT Annual Meeting, including registration details, please visit

About Vesigen Therapeutics

Vesigen Therapeutics is a biotechnology company developing a novel, non-viral delivery technology for gene editing, RNA, and protein-based therapeutics. Vesigen’s patented technology, called ARMMs (ARRDC1 Mediated Microvesicles), can be used to precisely deliver a wide range of payloads to a unique set of tissue and cell types. Vesigen has demonstrated highly efficient in vitro and in vivo functional delivery of a range of payloads across multiple cell types and is committed to developing transformative medicines that address current unmet medical needs. ARMMs were discovered and engineered into a drug delivery system at the Harvard T.H. Chan School of Public Health.

For additional information visit

Investor and Media Contact:

Adam Bero, Ph.D.
Kendall Investor Relations

LinkeIn Twitter